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Systems-Based Design
of Bi-Ligand Inhibitors of Oxidoreductases:
Filling the Chemical Proteomic Toolbox
factor binding site, coupled with the modular nature of
this gene family, has led us to develop a highly parallel
approach to inhibitor design. In this chemical proteomic
strategy, focused chemical libraries are tailored to sub-
families of large gene families to produce nM inhibitors
Daniel S. Sem,1,2,* Bonnie Bertolaet,2 Brian Baker,2,3
Edcon Chang,2 Aurora D. Costache,1
Stephen Coutts,2 Qing Dong,2 Mark Hansen,2
Victor Hong,2,4 Xuemei Huang,2
Richard M. Jack,2 Richard Kho,2 Henk Lang,2
Chen-Ting Ma,2 David Meininger,2,5 for multiple members of the subfamily. The parallel pro-
duction of inhibitors across a gene family such as theMaurizio Pellecchia,2,6 Fabrice Pierre,2
Hugo Villar,2 and Lin Yu2 oxidoreductases will have applications in chemogeno-
mic and functional genomic efforts to define protein1Chemical Proteomics Facility at Marquette
Department of Chemistry functions, as well as in drug design. The latter is a signifi-
cant point considering the large number of new proteinsMarquette University
P.O. Box 1881 and drug targets being identified as a result of functional
genomics efforts [4]. Inhibitors for various members ofMilwaukee, Wisconsin 53201
2 Triad Therapeutics, Inc. the oxidoreductase gene family could be used to gener-
ate chemical knockouts as a probe of protein function9381 Judicial Drive
San Diego, California 92121 in vivo (chemogenomics) or of protein-ligand interac-
tions in vitro (chemical proteomics). Such molecules, if
designed for optimal ADMET (adsorption, distribution.
metabolism, excretion, and toxicology) properties couldSummary
even serve as early-stage leads in a parallel drug discov-
ery program.Genomics-driven growth in the number of enzymes
of unknown function has created a need for better Such a systems-based approach to inhibitor design
requires a solid understanding of the common bindingstrategies to characterize them. Since enzyme inhibi-
tors have traditionally served this purpose, we present sites in a gene family. Since cofactor conformation is a
reflection of the common binding site shape, we hadhere an efficient systems-based inhibitor design strat-
egy, enabled by bioinformatic and NMR structural de- previously performed cluster analysis [5] on cofactors
extracted from 288 oxidoreductase crystal structures.velopments. First, we parse the oxidoreductase gene
family into structural subfamilies termed pharmaco- In that study [6], oxidoreductases clustered into subfam-
ilies termed pharmacofamilies that were related by co-families, which share pharmacophore features in their
cofactor binding sites. Then we identify a ligand for factor geometry, protein sequence, and protein fold
(SCOP classification). These structural proteomic stud-this site and use NMR-based binding site mapping
(NMR SOLVE) to determine where to extend a combi- ies are being extended and used herein to enable a
parallel/gene family-based approach to the design ofnatorial library, such that diversity elements are di-
rected into the adjacent substrate site. The cofactor bi-ligand inhibitors. NMR methods are used to design
bi-ligand libraries off of a privileged scaffold that occu-mimic is reused in the library in a manner that parallels
the reuse of cofactor domains in the oxidoreductase pies the cofactor site, which is conserved within the
pharmacofamily. The strategy is finally validated by thegene family. A library designed in this manner yielded
specific inhibitors for multiple oxidoreductases. identification of potent bi-ligand inhibitors for multiple
members of this pharmacofamily.
Introduction
Results and DiscussionProteomes are inherently modular since most domains
in proteins belong to superfamilies common to many
Structural Proteomic Analysis oforganisms [1–3], and proteins are generally thought to
Oxidoreductases: pharmacofamiliesbe created by gene duplication and shuffling of a limited
The conserved cofactor geometry for oxidoreductasesrepertoire of domains [1, 2]. For instance, oxidoreduc-
is apparent in Figure 1, where cofactors have been over-tases frequently use the same Rossmann fold domain
laid for members of the largest pharmacofamily, theto bind the NAD(P)(H) cofactor but use an additional
two-domain Rossmann fold proteins. There are two sub-unique domain for the substrate that defines the function
families that differ only by a 180 rotation around thefor a given enzyme. The presence of the conserved co-
glycosidic bond, with pharmacofamily 1 having the nico-
tinamide ring anti and pharmacofamily 2 having the nico-*Correspondence: daniel.sem@marquette.edu
3 Present address: Vertex Pharmaceuticals, Inc., 11010 Torreyana tinamide ring syn [6]. Especially relevant for the current
Road, San Diego, CA 92121. studies is that this conservation of cofactor geometry
4 Present address, Millennium Pharmaceuticals, Inc., 40 Lands- is paralleled by a conservation of binding site features
downe Street, Cambridge, MA 02139. that describe the pharmacophore for this family. The5 Present address, Tularik, Inc., 1120 Veteran’s Boulevard, South
conserved heteroatoms that define the hydrogen bondSan Francisco, CA 94080.
donors and acceptors that comprise this pharmaco-6 Present address, The Burnham Research Institute, 10901 N. Torrey
Pines Road, La Jolla, CA 92037. phore are shown in Figure 1C. The major oxidoreductase
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Figure 1. Pharmacofamilies 1 and 2
(A) Structure of the NADH cofactor bound by the oxidoreductases.
(B) Overlays of a unique subset of NAD(P)(H) geometries obtained from 288 crystal structures of oxidoreductases, yielding pharmacofamilies
related by the geometry of bound cofactor. The largest families are shown here, corresponding to the two-domain Rossmann fold enzymes
in pharmacofamilies 1 (anti) and 2 (syn).
(C) Corresponding pharmacophores for pharmacofamilies 1 and 2, with all protein heteroatoms indicated that are within hydrogen bonding
distance of atoms in the cofactor in the binding site. Regions occupied by Thr104 and Thr80 in E. coli DHPR (dihydrodipicolinate reductase)
are indicated for reference.
(D) Summary of the major pharmacofamilies that were previously derived based on parsing the oxidoreductases according to geometry of
bound cofactor [6]. Geometry around the C-N glycosidic bond connecting nicotinamide and ribose rings is indicated.
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Figure 2. Range of Calculated and Predicted Physicochemical Properties of Oxidoreductase Substrates as Well as Specificity Ligands (SLs)
Used in the Bi-Ligand Library
Key chemical properties of these diversity elements are compared with those for 460 known oxidoreductase substrates [7]. Calculated
properties are: (A) molecular weight; (B) AlogP, a measure of hydrophobicity; (C) number of hydrogen bond acceptors; and (D) number of
hydrogen bond donors.
pharmacofamilies are summarized in Figure 1D, and ini- there are a number with molecular weights in the 550
and 850 Da range, and some that are quite hydrophobic,tial studies reported herein focus on enzymes in phar-
macofamilies 1 and 2. The only differences between with AlogP (Ghose and Crippen water/octanol parti-
tioning [9]) values in excess of five.pharmacofamilies 1 and 2 is the placement of groups
around the carboxamide substituent on the nicotin-
amide ring. Noteworthy is the tendency of the carbonyl Modular Inhibitor Design Strategy to Parallel
a Modular Gene Familyof the carboxamides to point in the same direction, af-
fecting the relative placement of hydrogen bond donors Proteins that are evolutionarily related and have con-
served pharmacophore features in a binding site would(to the carboxamide C  O) and acceptors (from the
carboxamide NH2) within a pharmacofamily. be expected to have similar ligand binding preferences.
As such, our systems-based approach to the design ofThe binding site for the nicotinamide ring of the cofac-
tor is always close to the substrate site since the nicotin- bi-ligand inhibitors of oxidoreductases begins within a
pharmacofamily, initially chosen to be the two-domainamide ring is involved in a hydride transfer reaction with
the substrate. Although the binding site for the cofactor Rossmann fold family (Figure 1) because it is the largest
and most well-characterized pharmacofamily. Oxido-is conserved within a pharmacofamily, the adjacent sub-
strate site is quite variable. This variability is reflected in reductases, viewed in a systems-based manner, are
comprised of two adjacent binding sites: the NAD(P)Hthe diversity of substrates acted on by oxidoreductases.
We analyzed 460 oxidoreductase substrates [7] in terms cofactor (common ligand) and substrate (specificity li-
gand) binding sites, exemplified in Figure 3 with theof properties of interest in the drug design process [8]
(Figure 2). Although most oxidoreductase substrates are enzyme dihydrodipicolinate reductase (DHPR). The in-
hibitor design strategy used herein parallels the modularin the 100–180 Da range and of modest hydrophobicity,
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Figure 3. Comparison of Binding Modes for
Computationally Docked Cofactor Analog
and the NADH Cofactor
(A) Computationally docked structure of the
propylamide derivative of CLM-1 (white) in
the E. coli DHPR binding site, overlaid on the
NADH structure (yellow) and adjacent to the
2,6-pyridine dicarboxylate (PDC) substrate
analog (green). Docking was done with the
docking algorithm contained within the
MOE software package (Chemical Comput-
ing Group), with the MMFF94 forcefield and
with the 1arz coordinates for DHPR [10].
Binding site threonine residues are identified
in brown, with methyl groups rendered as
balls. Proximity of methyl groups on the
CLM’s propylamide group, Thr104, and
Thr170 to the PDC ligand is indicated with
dashed lines.
(B) A solvent-accessible surface map color
coded by partial charge (red, negative; blue,
positive), with the region surrounding the
negatively charged catechol oxygen shown
expanded. In the expansion, red is the sur-
face exposed para-hydroxyl group of CLM-1,
and the four surrounding blue regions repre-
sent guanido groups of arginines 81, 16, 39,
and 19 that approach within 5.5, 5.7, 7.0, and
9.0 A˚, respectively.
design of the oxidoreductase gene family [11] and pro- able substrate pocket. One of the inhibitors identified
in this screening process was modified to produce aduces inhibitors across a pharmacofamily, since it starts
by identifying a small molecule that binds in the common more potent and soluble analog by replacing a phenyl
ring with an acetic acid group, resulting in CLM-1 (Tableligand site (a common ligand mimic or CLM) for that
class of proteins. Diversity elements are then directed 1; Figure 4). The modeled structure of a propylamide
derivative of CLM-1 is shown docked into the bindingfrom the CLM into the adjacent specificity site in the
construction of a bi-ligand library. site of DHPR and overlaid on NADH (Figure 3A). The
docked structure binds in a mode that differs from that
originally predicted based on direct comparisons to co-Identification and Characterization of CLMs
We selected CLM candidates computationally by factor, which may be a reflection of an inherent symme-
try in the NADH molecule that has a nicotinamide ringmatching the pharmacophore properties of the nicotin-
amide mononucleotide portion of NADH bound to DHPR on one end and an adenine ring on the other. Indeed,
another low-energy docked structure had the propylam-[10], an oxidoreductase in pharmacofamily 1, and an
enzyme essential for cell wall synthesis in Mycobacte- ide group in the adenine site, but the orientation shown
here with the propylamide group proximal to the sub-rium tuberculosis [12]. This ligand-based search employed
the icosahedral matching algorithm [13] contained strate site is most consistent with the NMR SOLVE data
described below. The electrostatic surface shown inwithin the THREEDOM software package (Interprobe,
Inc.) to identify potential inhibitors, which were then Figure 3B indicates that the catechol ring is somewhat
solvent exposed and surrounded by positive chargepurchased and tested against DHPR as well as other
dehydrogenases in this pharmacofamily. The most density from adjacent arginines.
All computationally selected CLM candidates weredrug-like and crossreactive of these were resynthesized
and retested. Crossreactivity is a desired property, since commercially available and tested for binding potency
through steady-state kinetic inhibition studies witha CLM is effectively a privileged scaffold that is going
to provide baseline affinity across a pharmacofamily, DHPR, with a representative set of compounds shown
in Figure 4A. CLMs that bind at the NAD(P)(H) site werewith further increases in affinity later achieved for spe-
cific targets by directing bi-ligand libraries into the vari- identified based on inhibition profiles. For example,
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Table 1. Affinity and Specificity of CLM and Bi-Ligand Molecules for Oxidoreductases in pharmacofamilies 1 and 2
Structurea LDHb DHPRb DOXPRb
55 M 26 M 50 M
42 nMc 50 M 10 M
12 M 25 M 202 nMc
620 nM 100 nMc 7.9 M
a While the SL of the first bi-ligand was condensed with the carboxylic acid of the linker in Figure 5C, the other 2 SLs were condensed with
the acid of the shorter linker on CLM-1 [15].
b Numbers are Kis values except for DOXPR, which has an IC50, which should approximate a Kis. LDH (lactate dehydrogenase) and DHPR are
in pharmacofamily 1, while DOXPR (1-deoxy-D-xylulose-5-phosphate reductoisomerase) is in pharmacofamily 2 [6].
c Most potent inhibition value amongst the three enzymes is indicated in bold.
CLM-1 is a competitive inhibitor versus NADPH and, ments for key binding site residues to orient a CLM
candidate relative to where the reference cofactor hadtherefore, likely binds in the cofactor binding site. Inter-
estingly, the inhibition pattern showed a squared depen- bound. Although the acid version of the best CLM
(CLM-1, Table 1 and Figure 4) showed interaction pri-dence on concentration, suggesting that some synergy
might exist between sequential binding events to the marily between its catechol ring and the distal Thr80
(data not shown), the propylamide derivative in FigureDHPR tetramer. The fit was best to a competitive model,
with no apparent intercept effect in double reciprocal 5B showed a clear nuclear Overhauser effect (NOE) be-
tween the terminal methyl of the CLM and the 2,6-pyri-plots (Figure 4B).
dinedicarboxylate (PDC) substrate antagonist, which it-
self showed an NOE to the Thr104 interface residue.Determining the Expansion Point for the Bi-Ligand
Library with NMR SOLVE PDC also showed an NOE to a residue assigned to the
substrate site (Thr170). PDC is a stable analog of theWe then experimentally determined the CLM’s orienta-
tion and relative position in the cofactor binding site reactive dihydrodipicolinate substrate and is used here
to help mimic the ternary complex that would normallyby the NMR SOLVE method [11, 14]. The NMR SOLVE
method begins by mapping a binding site relative to a form in the steady-state catalytic cycle. Based on the
NOE to PDC, the end of the propylamide functionalityreference ligand, such as cofactor, and then characteriz-
ing the binding mode of a novel ligand, such as a CLM, therefore appears to be the appropriate place for at-
taching a specificity ligand. We then used a carboxylicrelative to the reference ligand. Key information ob-
tained with NMR SOLVE is where a linker should be acid functionality here as a bi-ligand library expansion
point. To verify that this functionality also resides in theplaced such that chemical diversity elements can be
attached and directed into an adjacent specificity substrate site, we compared 2D HMQC spectra (Figure
5C) for each version of this CLM, with and without thepocket. In order to avoid problems with spectral overlap
in 2D NMR experiments, studies were performed on terminal carboxylic acid (red and blue crosspeaks). This
chemical perturbation of the ligand caused the largestdeuterated and sparsely labeled protein, with the 1H-13C
label present only in the methyl groups of the 8-Met, changes in the crosspeak for Thr170, a residue known
to reside in the substrate site, and to a residue at the16-Ile, and 14-Thr residues in DHPR. Previously, we had
mapped the DHPR binding site with NADH as a refer- interface of the cofactor and substrate sites (Thr104).
These data largely confirmed the docked structure inence ligand [11] (Figure 5A). Now, we used these assign-
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residue at the interface of the NADH and PDC binding
sites. Structural data were included here only to illustrate
the method. The NMR data not only suggested the bi-
ligand library expansion point, but it also confirmed that
PDC binding mode was not significantly altered in the
CLM:PDC:DHPR ternary complex (compared to the
NADH:PDC:DHPR ternary complex), since PDC showed
the same pattern of NOEs to threonine methyl protons
in both complexes. Finally, the selective perturbation of
active site methyl proton chemical shifts in the complex
with CLM and the complex with the bi-ligand (see below)
allow us to rule out any nonspecific mechanism for inhi-
bition that could have produced competitive inhibition
profiles, at least for these inhibitors.
Validation of the NMR-Selected Library
Expansion Point
Based on these NMR data, CLM-1 was linked to PDC,
the specificity ligand analog. The corresponding bi-
ligand compound had a Kis of 100 nM, which represents
a 250-fold increase in affinity over the starting CLM
(Table 1). The common and specificity sites were both
occupied, based on NMR chemical shift mapping stud-
ies showing perturbations of residues in both binding
sites (Figure 5D). Although the squared effect on inhibi-
tion complicated steady-state analysis, analogous bi-
ligands were made with the same specificity ligand but
with variants of the CLM that gave less pronounced
cooperativity effects. Steady-state kinetic profiles for
two of these bi-ligand molecules are shown in Figure 6,
showing a best fit to a competitive inhibition model ver-
sus both the NADPH and dihydrodipicolinate substrates,
as expected for a bi-ligand inhibitor.
Building the Focused Bi-Ligand Library
The last step of this systems-based bi-ligand design
process involves the addition of diversity elements to
the CLM such that they are directed into the substrate
(specificity ligand [SL]) site in the manner suggested by
NMR SOLVE. Although the geometric relationship of the
Figure 4. Computationally Selected Cofactor Analogs and Steady- CLM and SL sites is conserved in oxidoreductases, the
State Characterization as a Cofactor Analog
actual size and electrostatic properties of the SL binding
(A) A representative set of 11 computationally selected and tested
site will vary in a way that parallels the diversity of sub-cofactor mimics, with the top structure being the only one that
strates used by oxidoreductases, as discussed above.showed significant inhibitory activity.
The diversity elements attached to the conserved CLM(B) Steady-state inhibition profile for CLM-1, which is a modified
form of the top inhibitor in (A). Profile is with inhibitor versus NADPH. scaffold were matched to the properties of substrates
Profile represents the fit to the equation for a competitive inhibitor used throughout the oxidoreductase gene family in that
with a squared dependence on inhibitor concentration. The fit gave they roughly paralleled the distribution of the chemical
a Kis value of 26  2 M. Curves for alcohol dehydrogenase (Kis  properties surveyed in Figure 2.101 M), lactate dehydrogenase (Kis  55 M), and DOXPR (Kis 
We selected 300 diversity elements (commercially50 M) fit best to a model for competitive inhibition.
available) and chemically joined them to the CLM-linker
construct. The resulting bi-ligand library was then screened
against three Rossmann-fold enzymes in pharmaco-Figure 3A, since the terminal methyl of the propylamide
is that part of the CLM that is closest to PDC (within families 1 and 2: DHPR, lactate dehydrogenase (LDH),
and 1-deoxy-D-xylulose-5-phosphate reductoisomer-5 A˚). It should be noted that the NMR SOLVE experi-
ments would have suggested the same library expan- ase (DOXPR). The starting CLM bound only weakly to
the three enzymes, with Kis values in the 25–100 Msion point in the absence of any protein structural infor-
mation, since crosspeaks for threonine residues were range (Table 1). However, after adding the diversity ele-
ments in the position selected with NMR SOLVE, steady-assigned based on proximity to reference ligands (NADH
and PDC). That is, it was never necessary to assign state enzyme kinetic screening identified a specific bi-
ligand inhibitor of LDH with a Kis of 42 nM and a bestThr104 to a specific residue number, as it would have
been adequate to view it only as the crosspeak for the fit to a model for competitive inhibition. This represents
Chemical Proteomic Tools: Bi-Ligand Inhibitors
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Figure 5. NMR SOLVE Data for DHPR
(A) The binding site is mapped relative to the NADH cofactor, identifying NMR probe atoms [14].
(B) NOESY data for a CLM-1 analog, which places the methyl terminus of the propylamide functionality closest to the SL site.
(C) Chemical alteration of the end of this alkyl chain in creating CLM-2 produces changes to crosspeaks for atoms in the SL site in the overlay
of HMQC spectra for complexes of DHPR with both versions of the CLM (red and blue).
(D) HMQC spectra of DHPR in the absence (red) and presence (blue) of the bi-ligand inhibitor.
an increase in affinity over the starting CLM of a thou- based bi-ligand design process described herein makes
fragment assembly more likely to produce inhibitors forsand-fold, with most of the increased affinity directed
toward specificity interactions, since the bi-ligand binds multiple, related proteins, since the CLM fragment pro-
vides a baseline of affinity across a pharmacofamilytwo to three orders of magnitude stronger to LDH than
to DHPR or DOXPR. We also identified a bi-ligand inhibi- (GCLM). Furthermore, since the mere joining of two mo-
lecular fragments has been proposed to provide astor that bound with an IC50 of 202 nM to DOXPR, also
with selectivity. Based on these data, we propose that much as 45 entropy units, corresponding to an increase
in affinity of 108-fold [19, 20] associated with the “chelatea bi-ligand collection of sufficient size and diversity,
built with an appropriately chosen CLM and well placed effect,” the combined effect of adding a CLM to an SL
could be as large as 108/KCLM fold. This could only occurlinkers, will produce nM inhibitors for most members of
a pharmacofamily. for those SLs binding in the specificity pocket adjacent
to the CLM, thus ensuring that linkage with the CLM
provides specificity for a given oxidoreductase. Al-Thermodynamic Foundation for Gene Family
Focused Bi-Ligand Libraries though the full magnitude of the chelate effect is still
being investigated by researchers, it is in any case quiteFragment-based assembly strategies are a very efficient
means of designing inhibitors [16–18]. The systems- large and reports of enhancements in affinity or rates
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Figure 6. Steady-State Inhibition Profiles for Bi-Ligand Molecules with CLMs that Are Variants of CLM-1
Bi-ligand structures are shown to the left of their respective inhibition profiles. Curves fit best to equations where inhibition was competitive
versus both cofactor (NADPH) and substrate. Enzyme was E. coli DHPR. The first bi-ligand was varied (0, 400, 750, 1100, 1500 nM) versus
NADPH and gave a Kis of 370  90 nM (A), and versus dihydrodipicolinate (DHP) gave a Kis of 170  50 nM (B). The second bi-ligand was
varied (0, 500, 1000, 1500, 2000 nM) versus NADPH and gave a Kis of 500  100 nM (C), and versus dihydrodipicolinate gave a Kis of 530 
140 nM (D).
approaching 108-fold have been reported [21]. In prac- source of drug leads for the many new targets being
identified in functional genomics efforts.tice, only a tiny fraction of this affinity increase will ever
be fully realized because linkers might be flexible, pro-
Experimental Proceduresduce nonoptimal placement of the CLM and SL ligands,
or have repulsive interactions with a binding site. Still,
Computational Search for CLMsthis combinatorial strategy for fragment linkage is an
Computational methods were used to identify CLM candidates to
efficient way of focusing a library, since even imperfect be tested as cofactor mimics. Coordinates of the nicotinamide mo-
linkage can produce large affinity boosts for multiple nonucleotide (NMN) portion of the NADH cofactor were extracted
enzymes within a pharmacofamily. from the structure of cofactor in complex with DHPR (pdb code:
1arz). These coordinates were used to search against databases of
commercially available compounds (such as from ASINEX [Moscow,
Russia]), which contained molecules with precalculated three-Significance
dimensional structures. The search was quite fast since it involved
only matching the shape of the NMN portion of the cofactor to theGenomes have now been sequenced for numerous
precalculated structures in the small molecule database through anorganisms, and expectations are that this information
icosahedral matching algorithm [13, 22]. Still, an ellipsoid shape
will provide a better understanding of biology, as well prefilter was used as a first screen to identify molecules that were
as yield new and better therapeutics. This cannot be roughly the shape of NMN to prescreen and eliminate obviously
poor matches. To address heteroatom composition and hydrogenrealized until more efficient strategies are developed
bonding capabilities at an approximate level, hybrid shape-match-to characterize proteins, and tools are created to
ing scores were used. Shapes were compared both as a function oftranslate this knowledge into inhibitors as mechanistic
all atoms and as a function of heteratoms only, with scores weightedprobes and drugs. To this end, we had previously re-
equally in the hybrid score. After prefiltering the circa 40,000 mole-
ported a structural proteomic analysis of oxidoreduc- cules, shape-matching scores were calculated with the THREEDOM
tases, which comprise 2%–4% of most proteomes [6]. software package by comparing full structures or only the hetera-
toms. These two sets of scores were combined to create an averageHerein, we presented a systems-based strategy for
“hybrid” score through Perl scripts developed in-house. Generallydesigning inhibitors of oxidoreductases. This strategy
around 5% of the computationally selected compounds were foundparallels nature’s modular approach for designing the
to inhibit one of the three dehydrogenases tested. Althoughoxidoreductase gene family itself. Chemical libraries
searches against the full-length NADH cofactor produced a some-
designed in this manner could be used as a source of what higher hit rate (up to 10% versus lactate dehydrogenase), these
chemogenomic probes for defining functions of mem- compounds were not used due to their higher molecular weight and
unsuitability as drug leads.bers of the oxidoreductase gene family, as well as a
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Computational Docking of the Propylamide dence on inhibitor concentration (Figure 4B), still fitting best to a
competitive model:Derivative of CLM-1
The propylamide derivative of CLM-1 was docked into the crystal
structure of the DHPR/NADH/2,6-PDC ternary complex after remov- v 
Vmax A
A  Km (1  (I/Kis)2)ing the cofactor. First, the ligand was minimized by AM1
(Gaussian98) with a net charge of –1, localized on the para-hydroxy
where v is the initial velocity, I is inhibitor concentration, Kis is thegroup of the catechol ring. Docking was then performed with the
slope inhibition constant, A is cofactor (NADH) concentration, VmaxMOE software package (Chemical Computing Group) and the
is the maximum velocity, and Km is the Michaelis constant.MMFF94 forcefield, with ligand flexible and protein kept rigid. Pro-
tein was also energy minimized (MMFF94) before docking, and then
NMR Spectroscopy25 docking runs were performed with random starting orientations.
NMR experiments were performed on a Bruker DRX700 spectrome-Optimization was with simulated annealing, with an initial tempera-
ter equipped with a triple resonance probe and triple axis gradientture of 1000 K and six cycles per run. Docking calculations included
coil. Tetrameric DHPR concentration was 75 M (300 M mono-protein atoms within a 62 A˚ 	 62 A˚ 	 62 A˚ box surrounding the
mer) in 25 mM Tris-D11 buffer (pH 7.8) at a temperature of 303 K,site previously occupied by cofactor. The choice to dock into the
with a sample volume of 150 l in Shigemi tubes, as describedcofactor site was based on the observation of competitive inhibition
previously [14]. Most NMR experiments were performed in the pres-patterns (with the more soluble CLM-1) versus cofactor in the
ence of the PDC substrate analog along with either NADH or CLM,steady-state enzyme kinetic studies described below. One of the
in order to mimic the active ternary complex that is produced in thetwo lowest energy structures is shown in Figure 3A, with the NADH
steady-state catalytic cycle. PDC was not used for studies of bi-structure overlaid back in its original orientation so that the relative
ligands or for the inhibitors being compared in Figure 5C. PDC is abinding mode of CLM-1 derivative and “reference” cofactor can be
fairly potent substrate analog, with a Kis value of 26 M versuscompared. Although the lowest energy structure had the propylam-
the dihydrodipicolinate substrate [24]. Selective WURST adiabaticide group extending into the adenine site, only the orientation shown
decoupling [26] of the 
 from the  13C of Thr was used in NMRin Figure 3A was consistent with the NMR SOLVE data described
experiments to decrease overlap of the 14 Thr residues. Typical 2Dbelow. A solvent-accessible surface map color coded by partial
[13C,1H] HMQC spectra were recorded in 30 min. Typical 2D [1H,1H]charge is shown in Figure 3B, with the region surrounding the nega-
NOESY spectra were acquired with 256 	 2048 complex points andtive (red) catechol ring shown in the expansion. The four surrounding
with mixing times between 50 and 500 ms. 13C decoupling duringblue regions represent guanido groups of arginines 81, 16, 39, and
acquisition was with a GARP composite decoupling sequence [27],19 that approach within 5.5, 5.7, 7.0, and 9.0 A˚, respectively, of the
while 13C
 decoupling during the evolution period was with a 180charged oxygen of the catechol ring.
refocusing pulse. Ambiguities due to proton overlap among Thr and
Met methyl proton chemical shifts were removed by recording a 3DSynthesis of Bi-Ligand Library
[13C,1H] resolved [1H,1H] NOESY experiment [28]. NOEs were laterThe 3,4-dihydroxyphenylmethylene-rhodanine CLM (CLM-1) was
verified as not being due to spin diffusion through the QUIET-NOESYsynthesized by heating a solution of 13.6 g 3,4-dihydroxybenzalde-
experiment [29, 30].hyde, and 19.3 g rhodanine acetic acid at 95C in 200 ml acetic acid
for 6 hr. After cooling the solution, the precipitate was collected
Acknowledgmentsand washed with acetic acid (2 	 5 mL) to give 20 g of product
CLM-1. The CLM-1 acid (or amine; 1.5 eq) and PS-carbodiimide
We thank Dr. John Blanchard (Albert Einstein College of Medicine,resin (2 eq) were reacted in THF (10 mL/g) for 1 hr. The desired
NY) for the original pET11a DHPR expression construct. The workamine (or acid) to be conjugated to the CLM-1 was then added
described in this article was performed at Triad Therapeutics, with(1 eq) and reacted overnight. Product was extracted twice with THF
the exception of the modeling in Figure 3, which was done by A.D.C.and solvent evaporated to give desired product.
at Marquette University.
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